171 related articles for article (PubMed ID: 22607879)
1. Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.
Cilibrizzi A; Schepetkin IA; Bartolucci G; Crocetti L; Dal Piaz V; Giovannoni MP; Graziano A; Kirpotina LN; Quinn MT; Vergelli C
Bioorg Med Chem; 2012 Jun; 20(12):3781-92. PubMed ID: 22607879
[TBL] [Abstract][Full Text] [Related]
2. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
Giovannoni MP; Schepetkin IA; Cilibrizzi A; Crocetti L; Khlebnikov AI; Dahlgren C; Graziano A; Dal Piaz V; Kirpotina LN; Zerbinati S; Vergelli C; Quinn MT
Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists.
Cilibrizzi A; Crocetti L; Giovannoni MP; Graziano A; Vergelli C; Bartolucci G; Soldani G; Quinn MT; Schepetkin IA; Faggi C
Chirality; 2013 Jul; 25(7):400-8. PubMed ID: 23744588
[TBL] [Abstract][Full Text] [Related]
4. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
Cilibrizzi A; Quinn MT; Kirpotina LN; Schepetkin IA; Holderness J; Ye RD; Rabiet MJ; Biancalani C; Cesari N; Graziano A; Vergelli C; Pieretti S; Dal Piaz V; Giovannoni MP
J Med Chem; 2009 Aug; 52(16):5044-57. PubMed ID: 19639995
[TBL] [Abstract][Full Text] [Related]
5. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
6. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
7. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
9. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
[TBL] [Abstract][Full Text] [Related]
10. High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Quinn MT
Mol Pharmacol; 2007 Apr; 71(4):1061-74. PubMed ID: 17229869
[TBL] [Abstract][Full Text] [Related]
11. Substituted Pyridazin-3(2 H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists.
Deora GS; Qin CX; Vecchio EA; Debono AJ; Priebbenow DL; Brady RM; Beveridge J; Teguh SC; Deo M; May LT; Krippner G; Ritchie RH; Baell JB
J Med Chem; 2019 May; 62(10):5242-5248. PubMed ID: 31038950
[TBL] [Abstract][Full Text] [Related]
12. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
Schepetkin IA; Khlebnikov AI; Giovannoni MP; Kirpotina LN; Cilibrizzi A; Quinn MT
Curr Med Chem; 2014; 21(13):1478-504. PubMed ID: 24350845
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
14. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Khlebnikov AI; Ye RD; Quinn MT
Bioorg Med Chem; 2016 Jun; 24(11):2530-2543. PubMed ID: 27134116
[TBL] [Abstract][Full Text] [Related]
15. Relationship of ligand-receptor dynamics to actin polymerization in RBL-2H3 cells transfected with the human formyl peptide receptor.
Hall AL; Wilson BS; Pfeiffer JR; Oliver JM; Sklar LA
J Leukoc Biol; 1997 Oct; 62(4):535-46. PubMed ID: 9335325
[TBL] [Abstract][Full Text] [Related]
16. Chiral resolution and absolute configuration of the enantiomers of 5-acetyl-2-methyl-4-methylsulfinyl-6-phenyl-3(2H)-pyridazinone and evaluation of their platelet aggregation inhibitory activity.
Azzolina O; Dal Piaz V; Collina S; Giovannoni MP; Tadini C
Chirality; 1997; 9(7):681-5. PubMed ID: 9366028
[TBL] [Abstract][Full Text] [Related]
17. Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.
Giovannoni MP; Ciciani G; Cilibrizzi A; Crocetti L; Daniele S; Di Cesare Mannelli L; Ghelardini C; Giacomelli C; Guerrini G; Martini C; Trincavelli ML; Vergelli C
Eur J Med Chem; 2015 Jan; 89():32-41. PubMed ID: 25462223
[TBL] [Abstract][Full Text] [Related]
18. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
19. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
20. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.
Sogawa Y; Shimizugawa A; Ohyama T; Maeda H; Hirahara K
J Pharmacol Sci; 2009 Nov; 111(3):317-21. PubMed ID: 19926937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]